By Bruce Sylvester ORLANDO, Florida (Reuters Health) Oct 21 –
A retrospective analysis of pooled data from two 12-month phase III trials indicates that bimatoprost (Lumigen) is effective in treating African Americans with glaucoma, researchers reported here Sunday at the annual meeting of the American Academy of Ophthalmology.
This is an advance over conventional treatment of glaucoma with timolol. Glaucoma affects African Americans at a 6-to-8 times higher rate than individuals of other races and is the cause of blindness after diagnosis at a 14-to-17 times higher rate, lead investigator Dr. Eve Higginbotham of the University of Maryland School of Medicine in Baltimore told Reuters Health.
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!